

---

# **Migraine: Developing Drugs for Acute Treatment Guidance for Industry**

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)**

**February 2018  
Clinical/Medical**

---

# **Migraine: Developing Drugs for Acute Treatment Guidance for Industry**

*Additional copies are available from:*

*Office of Communications, Division of Drug Information  
Center for Drug Evaluation and Research  
Food and Drug Administration  
10001 New Hampshire Ave., Hillandale Bldg., 4th Floor  
Silver Spring, MD 20993-0002*

*Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353; Email: [druginfo@fda.hhs.gov](mailto:druginfo@fda.hhs.gov)  
<https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>*

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)**

**February 2018  
Clinical/Medical**

## TABLE OF CONTENTS

|             |   |          |
|-------------|---|----------|
| <b>I.</b>   | <b>INTRODUCTION</b> .....                               | <b>1</b> |
| <b>II.</b>  | <b>BACKGROUND</b> .....                                 | <b>2</b> |
| <b>III.</b> | <b>DEVELOPMENT PROGRAM</b> .....                        | <b>2</b> |
| <b>A.</b>   | <b>Trial Population</b> .....                           | <b>2</b> |
| <b>B.</b>   | <b>Efficacy Considerations</b> .....                    | <b>3</b> |
| 1.          | <i>Trial Design</i> .....                               | 3        |
| 2.          | <i>Trial Population and Entry Criteria</i> .....        | 3        |
| 3.          | <i>Dose Selection</i> .....                             | 4        |
| 4.          | <i>Concomitant Medications</i> .....                    | 4        |
| 5.          | <i>Efficacy Endpoints</i> .....                         | 4        |
| 6.          | <i>Trial Procedures and Timing of Assessments</i> ..... | 5        |
| 7.          | <i>Statistical Considerations</i> .....                 | 5        |
| <b>C.</b>   | <b>Safety Considerations</b> .....                      | <b>6</b> |
| <b>D.</b>   | <b>Other Considerations</b> .....                       | <b>7</b> |
| 1.          | <i>Pediatric Studies</i> .....                          | 7        |
| 2.          | <i>Labeling Considerations</i> .....                    | 8        |

## **Migraine: Developing Drugs for Acute Treatment Guidance for Industry<sup>1</sup>**

This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA office responsible for this guidance as listed on the title page.

### **I. INTRODUCTION**

The purpose of this guidance is to assist sponsors in the clinical development of prescription drugs for the acute treatment of migraine.<sup>2</sup> Specifically, this guidance addresses FDA's current thinking regarding the overall development program and clinical trial designs to support approval of prescription drugs for the acute treatment of migraine.<sup>3</sup> This guidance does not apply to over-the-counter drug products. This guidance also does not address the development of drugs indicated to reduce the frequency of migraine attacks. Such development will be addressed separately in a future guidance.

This guidance does not contain discussion of the general issues of statistical analysis or clinical trial design. Those topics are addressed in the ICH guidances for industry *E9 Statistical Principles for Clinical Trials* and *E10 Choice of Control Group and Related Issues in Clinical Trials*, respectively.<sup>4</sup>

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of

---

<sup>1</sup> This guidance has been prepared by the Division of Neurology Products in the Center for Drug Evaluation and Research at the Food and Drug Administration.

<sup>2</sup> For the purposes of this guidance, all references to *drugs* include both human drugs approved under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and therapeutic biological products licensed under section 351 of the Public Health Service Act unless otherwise specified. When used in this guidance, the term *drugs* refers to prescription drugs unless otherwise specified.

<sup>3</sup> In addition to consulting guidances, sponsors are encouraged to contact the Division to discuss specific issues that arise during the development of drugs for the acute treatment of migraine.

<sup>4</sup> We update guidances periodically. To make sure you have the most recent version of a guidance, check the FDA Drugs guidance web page at <https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>.

## *Contains Nonbinding Recommendations*

the word *should* in Agency guidances means that something is suggested or recommended, but not required.

## **II. BACKGROUND**

Migraine is a chronic neurovascular disorder characterized by recurrent attacks of often severe headache, typically accompanied by nausea and sensitivity to light and/or sound. In adults, migraine attacks usually last from 4 to 72 hours. Migraine headache is typically throbbing, unilateral, and aggravated by physical activity. Criteria proposed by the International Headache Society (IHS) require a combination of some of these characteristics and associated symptoms in at least five attacks to establish a diagnosis of migraine.<sup>5</sup>

There are two major subtypes of migraine: migraine without aura (also called *common migraine*) and migraine with aura (also called *classic migraine*). Migraine with aura is characterized by focal neurological symptoms that typically precede, or sometimes accompany, the headache. These focal neurological symptoms are absent in migraine without aura. Some patients may present with both subtypes of migraine.

Pharmacologic approaches to the treatment of migraine include drugs to treat acute migraine attacks as they arise (acute treatment of migraine), and drugs to reduce the frequency of migraine attacks (preventive treatment). This guidance addresses the development of drugs for the acute treatment of migraine.

## **III. DEVELOPMENT PROGRAM**

### **A. Trial Population**

Either healthy adult volunteers or migraine patients can be enrolled in initial phase 1 trials. Because migraine patients are predominantly female, it is important to enroll, early in development (i.e., by the beginning of phase 2), women of child-bearing potential who are practicing effective contraception.

Because migraine peak incidence is during adolescence, and onset in younger children is not uncommon, pediatric studies of children are required under section 505B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c). Sponsors are encouraged to begin discussions about their pediatric clinical development plan early in development because sponsors are required to submit pediatric study plans no later than 60 days<sup>6</sup> after an end-of-phase 2 meeting.<sup>7</sup>

---

<sup>5</sup> See <http://ihs-classification.org/en/>.

<sup>6</sup> Or such other time as agreed upon.

<sup>7</sup> See section 505B(e)(2)(A)(ii)(I) of the FD&C Act (21 U.S.C. 355c(e)(2)(A)(ii)(I)).

## *Contains Nonbinding Recommendations*

### **B. Efficacy Considerations**

Typically, at least two adequate and well-controlled trials are needed to support approval of a new molecular entity. A single adequate and well-controlled trial may be sufficient to support approval of a new route of administration for a drug already approved for the acute treatment of migraine, for treatment of a new subpopulation (e.g., for the pediatric population) or for a drug already approved for the prophylaxis of migraine (see the guidance for industry *Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products*).

#### *1. Trial Design*

In general, efficacy trials should use a randomized, double-blind, placebo-controlled, parallel group design. Although a comparison of a single dose level with placebo can be used to support efficacy of a drug, it is usually preferable to study at least two doses.

The timing of drug administration should be defined in the protocol. Although drug administration as early as practicable during the course of acute migraine is typically recommended by migraine experts, evidence should be obtained that the investigational drug is able to treat a migraine headache of moderate or severe intensity, because many patients reach that level of pain. Therefore, in efficacy trials intended to support approval, migraine patients should take the investigational drug as soon as they experience a migraine headache of moderate or severe intensity. It is also important to collect sufficient baseline information about the headache (i.e., headache intensity, presence or absence of associated symptoms, unilaterality or bilaterality of the headache, aggravation by exercise, throbbing or nonthrobbing) to be able to verify that the headache treated was, in fact, acute migraine. Additional trials assessing drug response after treatment of acute migraine at the mild pain stage can be conducted, and can be described in labeling.

Typically, efficacy trials should assess the effectiveness of a single administration of the investigational drug to treat a single acute migraine episode. To assess the safety and efficacy of redosing (e.g., in case of recurrence of migraine symptom(s) or an incomplete response), patients should be re-randomized to investigational drug or control.

#### *2. Trial Population and Entry Criteria*

Patients enrolled in clinical trials should have a diagnosis of migraine, with or without aura, according to established IHS criteria. The age at the time of initial migraine diagnosis should be younger than 50 years, to decrease the chance of enrolling patients with other disorders.

The time since initial diagnosis should be at least 1 year. Patients with coexisting types of headaches (e.g., tension-type headaches) can be included in the trial if the other headaches are distinguishable from migraine headache by the patient.

## *Contains Nonbinding Recommendations*

### *3. Dose Selection*

The first controlled trials should explore a range of doses to assess the dose-response relationship and provide a basis for dose selection in definitive efficacy trials. Some data should be collected on doses above and below what appears to be the optimal dose, and an effort should be made to identify the lowest dose that provides a desirable treatment effect. It is advisable, whenever feasible, to obtain plasma drug level data in patients. Establishing a plasma concentration (exposure)-response relationship can be useful to support dosing recommendations based on specific patient characteristics (e.g., body weight, renal function).

### *4. Concomitant Medications*

During the conduct of early trials, and until the drug's metabolism is adequately understood, concomitant medications should be avoided. Assuming no important drug-drug interactions are anticipated, concomitant medications to reduce the frequency of migraine episodes can be used in later stage trials, but only if the dosage of those concomitant medications has been stable for at least 3 months before inclusion into the trial. If the trial population includes patients with and without concomitant treatment to reduce the frequency of migraine episodes, randomization should be stratified by use/non-use of such concomitant treatment. If drugs used for the preventive treatment of migraine have been withdrawn, withdrawal should be complete at least 1 month before trial entry.

It is important that patients avoid any analgesic or other acute migraine medication(s) for at least 24 hours before treatment with the investigational drug to reduce confounding factors. Use of rescue medication must be allowed, but patients should be encouraged to wait at least 2 hours after initial treatment before using rescue medication. Rescue medication can consist of the patient's usual acute treatment of migraine, unless this treatment has the potential for an adverse interaction with the investigational drug (e.g., 5-HT<sub>1</sub> agonist or ergot alkaloid medications should be avoided within 24 hours of any investigational 5-HT<sub>1</sub> agonist or vasoactive drug use).

### *5. Efficacy Endpoints*

Because migraine is a complex disorder characterized by several associated symptoms (i.e., nausea, photophobia, and phonophobia) in addition to headache, a drug effect on headache pain alone is not considered sufficient to grant a claim for the acute treatment of migraine. In the past, approval of drugs for the acute treatment of migraine was based on the demonstration of an effect on four co-primary endpoints: pain, nausea, photophobia, and phonophobia. This approach remains acceptable.

A preferred approach, which aims to better align the study outcome with the symptom(s) of primary importance to patients, is to demonstrate an effect on both pain and the patient's most bothersome symptom. Patients are asked to identify their most bothersome migraine-associated symptom in addition to pain. The identification can take place either before the attack is treated (e.g., at the baseline visit), or at the time of the attack, but before administration of the study drug. Using this approach, the two co-primary endpoints are (1) having no headache pain at 2 hours after dosing and (2) a demonstrated effect on the most bothersome migraine-associated symptom

## *Contains Nonbinding Recommendations*

at 2 hours after dose. Regardless of the associated symptom identified as most bothersome, all three important migraine-associated symptoms (i.e., nausea, photophobia, and phonophobia) should be assessed separately as secondary endpoints.

Migraine-associated headache pain and associated symptoms should be measured by asking patients to self-report the current status of their headache pain and associated symptoms. A four-point Likert scale should be used for headache pain (i.e., 0=none, 1=mild, 2=moderate, 3=severe), and a binary scale (present or absent) should be used for associated symptoms.

The following additional secondary endpoints should be assessed in efficacy trials:

- The proportion of patients achieving “no headache pain” at various time points following treatment. For this analysis, it is especially useful to record the time that no headache pain is first noted.
- The proportion of patients requiring additional medication (either a second dose or rescue medication) within 24 hours of initial treatment.
- The proportion of patients who are “sustained pain-free,” defined as having no headache pain at 2 hours after dose, with no use of rescue medication and no relapse of headache pain within 24 hours (24-hour sustained pain-free) or 48 hours (48-hour sustained pain-free) after administration of the investigational drug. The proportion of patients who are sustained pain-free should not be used as a primary endpoint, because it is possible to show a significant effect on the proportion of patients who are sustained pain-free without any significant drug effect on individual migraine symptoms (including pain) by the 2-hour time point.
- The incidence of pain relapse, defined as the return of headache of any severity within 48 hours after administration of the investigational drug, when the patient was pain-free at 2 hours after investigational drug administration.

### *6. Trial Procedures and Timing of Assessments*

The treatment observation period should be at least 48 hours and include data collection at prespecified time points during the observation period (e.g., 0, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours). For outpatient trials, the patient should be instructed to record all data in a headache diary. The headache diary should be shown to be well defined and reliable for the target population based on the recommendations described in the guidance for industry *Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims*.

### *7. Statistical Considerations*

The typical primary efficacy analysis should compare, between treatment groups, the proportion of patients with no headache pain at 2 hours after dosing (i.e., going from a pain score of 2 or 3 at baseline to a score of 0 at 2 hours) and the proportion of patients with absence of the “most bothersome associated symptom” at 2 hours after dosing. No correction for multiple comparisons



## ***Contains Nonbinding Recommendations***

is necessary for these two co-primary endpoints, because both must show a statistically significant effect of treatment.

Secondary endpoints expected by FDA in acute migraine trials are described under section III.B.5., Efficacy Endpoints. Additional secondary endpoints may be considered. Ordering of secondary endpoints should be based on the trial objectives and intended claims in labeling. Typically, secondary endpoints to be described in labeling should not be duplicative of the primary endpoints. It is important to define prospectively the secondary endpoints, and include a statistical plan to control the Type-I error rate for the multiple comparisons.

### **C. Safety Considerations**

Acute migraine headaches are treated long term and intermittently. Therefore, the safety database intended to support approval should follow the same general paradigm as for chronic-use drugs, including the conduct of at least one long-term safety trial during which patients can treat all acute migraine episodes with the investigational drug.

Because phase 3 trials are typically conducted in the outpatient setting, phase 1 and early phase 2 trials, during which the investigational drug is administered under close medical supervision, provide the best opportunity to obtain vital sign and laboratory data at times close to investigational drug administration. These trials should include vital signs, hematology, serum chemistry, urinalysis, and 12-lead electrocardiogram at appropriate intervals. Vital signs and electrocardiography should be assessed around expected  $C_{max}$  for the investigational drug and major metabolites. During most short-term phase 2 and phase 3 outpatient trials, baseline and post-treatment vital signs and laboratory assessment should be conducted. Safety data during long-term phase 3 trials should be obtained at appropriate intervals, taking into consideration the results of nonclinical studies and earlier human experience with the investigational drug and with other drugs of the class.

New molecular entities should follow the safety recommendations in the ICH guidance for industry *E1A The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions*. To be counted in the long-term safety database, adult patients should treat, on average, a minimum of two migraine attacks per month. The safety experience should be at relevant doses and frequency of administration, including a substantial experience at the highest dose and highest frequency of administration proposed for marketing.

If the drug has the potential to have adverse vascular effects, additional nonclinical studies (e.g., in vitro studies to assess coronary artery vasoconstriction) and safety studies in populations at risk (e.g., patients with known coronary artery disease) may be needed. Consultation with the Division is advised early in the development program.

## *Contains Nonbinding Recommendations*

### **D. Other Considerations**

#### *1. Pediatric Studies*

Migraine is a relatively common disorder in children. There are reasons to believe that migraine in the adult and pediatric populations are substantially different clinical entities and one cannot assume that a drug effective in adults will also be effective in children. Therefore, studies in the pediatric population are needed. Because migraine is rare in children younger than 6 years old, a partial waiver for the conduct of studies in this age group generally will be granted. Sponsors are encouraged to begin discussions about their pediatric clinical development plan early in development because they are required to submit pediatric study plans no later than 60 days<sup>8</sup> after an end-of-phase 2 meeting.<sup>9</sup> Pediatric studies should evaluate patients aged 6 to 17 years. Because disease characteristics change with puberty, pediatric studies should include adequate numbers of patients to characterize safety and efficacy of the drug across the entire pediatric age range. Migraine diagnosis should be based on IHS criteria. We recommend that sponsors refer to the Pediatric Research Equity Act as amended by the Food and Drug Administration Reauthorization Act of 2017<sup>10</sup> to review requirements for submission of an initial pediatric study plan.<sup>11</sup>

Before initiation of a clinical efficacy trial, the pharmacokinetics of the drug in the pediatric population should be assessed and compared with the pharmacokinetics of the drug in adults. This permits proper dose selection for pediatric efficacy and safety studies. The development of an age-appropriate formulation should also be considered as needed.

Sponsors can consider the following two options for their pediatric efficacy studies programs:

- (1) Conduct separate efficacy studies, one in patients aged 12 to 17 years and a second in patients aged 6 to 11 years (each powered to show efficacy).
- (2) Conduct a single efficacy study in patients aged 6 to 17 years, with a sufficient number of patients in the 6- to 11-year and 12- to 17-year subgroups to be able to characterize the efficacy (and safety) of the drug in each subgroup adequately (but without a need to achieve statistical significance in each subgroup).

---

<sup>8</sup> Or such other time as agreed upon.

<sup>9</sup> See section 505B(e)(2)(A)(ii)(I) of the FD&C Act (21 U.S.C. 355c(e)(2)(A)(ii)(I)).

<sup>10</sup> See section 505B of the FD&C Act (21 U.S.C. 355c).

<sup>11</sup> See also the draft guidance for industry *Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans*. When final, this guidance will represent the FDA's current thinking on this topic.

## *Contains Nonbinding Recommendations*

Because of the high placebo response rate in pediatric migraine studies, an enrichment strategy<sup>12</sup> should be considered to increase the chance of demonstrating a drug effect. An approach that has proven successful in several pediatric trials is, during a migraine attack, to first administer single-blind placebo to all patients, and then randomize only those patients who did not achieve freedom from pain at 30 minutes to the investigational drug or placebo. Also, only patients whose migraine attacks typically last at least 3 hours should be included. The proportion of patients pain-free at 2 hours after administration of the investigational drug should be the primary endpoint. An approach that evaluates pain and another symptom (i.e., co-primary endpoints) is not needed for pediatric studies. Migraine-associated symptoms should be evaluated as secondary endpoints. Other secondary endpoints as described above for adult trials also should be evaluated, again with control of the Type-I error rate.

A 1-year long-term pediatric safety study should be conducted. Generally, if the drug is already approved in adults, the pediatric safety database should include data on at least 200 patients treating, on average, one migraine attack per month for 6 months; and 75 patients treating, on average, at least one migraine attack per month for 1 year. That study should evaluate the effect of treatment on growth, cognition, and endocrine development. A juvenile animal toxicology study in a single species (typically rat) should be conducted prior to initiation of the long-term pediatric safety study.

### *2. Labeling Considerations*

Over the past 2 decades, FDA has approved several new drugs indicated for the treatment of acute migraine for marketing in the United States. The majority of these are selective 5-HT<sub>1B/1D</sub> receptor agonists and thus belong to the drug class referred to as triptans. The principal safety concern with triptans relates to their ability to cause coronary or peripheral arterial constriction that may result in serious adverse cardiac or peripheral vascular events. As a result, FDA has adopted certain standard or class labeling for triptans. Future investigational drugs with similar pharmacological activity will be subject to this class labeling, unless it can be shown that the drug does not have vasoconstrictive effects. Also, new drugs of other pharmacological classes that also have the potential for vasoconstrictive effects probably would be subject to similar class labeling.

The latest approved labeling for a member of this class should form the basis, or template, for labeling of new drugs that share a similar mechanism of action, or have similar safety issues (e.g., coronary vasoconstriction). As is always the case, additional information regarding the safe use of a drug should be included in the appropriate sections of labeling, even though it may not be described in this guidance.

The recommendations for the following labeling sections apply to all new drugs indicated for the acute treatment of migraine.

---

<sup>12</sup> See the draft guidance for industry *Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products*. When final, this guidance will represent the FDA's current thinking on this topic.

## *Contains Nonbinding Recommendations*

- **INDICATIONS AND USAGE**

This section should be brief and should state that the drug is indicated for the acute treatment of migraine with or without aura.

- **DOSAGE AND ADMINISTRATION**

This section should include the following information:

- The minimum interval between doses to treat the same acute migraine episode (i.e., if the migraine episode has not resolved by 2 hours after taking the drug, or returns after transient improvement). Re-dosing information should be described in labeling only if information supporting the safety and efficacy of re-dosing is included in the marketing application.
- The average number of acute migraine episodes within a 30-day period that can be treated safely (based on data obtained from the long-term safety trials).

- **WARNINGS AND PRECAUTIONS**

This section should include a description of medication overuse headache as follows:

*Medication Overuse Headache*

*Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, or a combination of drugs for 10 or more days per month) may lead to exacerbation of headache (i.e., medication overuse headache). Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks.*

*Detoxification of patients including withdrawal of the overused drugs and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary.*

- **CLINICAL STUDIES**

This section should describe the efficacy trials from which evidence of effectiveness was obtained.

This section should include a figure derived using a Kaplan-Meier survival analysis method showing the estimated probability of achieving an initial headache response within the first 2 hours following the initial dose. Pooled efficacy data from similarly designed controlled trials can be used to generate these graphs. If there are dose-response data, these should be shown. A brief statement describing the dose-response relationship of the drug, as well as brief statements regarding efficacy in important subgroups (e.g., sex, age, and race) also should be included.